# Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis

> **NCT00954915** · PHASE1,PHASE2 · TERMINATED · sponsor: **MacroGenics** · enrollment: 1 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **BIOLOGICAL:** teplizumab

## Key facts

- **NCT ID:** NCT00954915
- **Lead sponsor:** MacroGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-12
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Injection site reaction met protocol-defined stopping criteria.
- **Last updated:** 2022-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00954915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00954915, "Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT00954915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*